• The excellent safety profile of solanezumab and

  2024-08-01

  

  The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr

• About this report Alzheimer s Disease

  2024-08-01

  

  About this report 2018 Alzheimer's Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer's disease, the most common cause of dementia. Background and context for interpreting the data are contained in the Overview. Additional sections address prevalence, mortality a

• br Materials and methods br

  2024-08-01

  

  Materials and methods Results Discussion Knowledge of the molecular basis of an inherited genetic disease is crucial for understanding the disease pathology and, ultimately, for therapeutic design. Several recent reports have stressed the need for physical characterization of disease-associ

• Cancers that responded to immune checkpoint inhibitors

  2024-08-01

  

  Cancers that responded to immune checkpoint inhibitors were shown to present a type I interferon (IFN) signature in the TME 33, 34. Type I IFNs positively regulate the expression of tumor antigens and their crosspresentation by DCs to tumoricidal CTLs. Furthermore, CD8+ T cell develops full effector

• Interestingly our transgenic mouse model with macrophages ex

  2024-08-01

  

  Interestingly, our transgenic mouse model with macrophages expressing AdipoR1 showed not only improved insulin sensitivity and inflammation in skeletal muscle and adipose tissues, but fat mass, macrophage and plasma lipid accumulation and foam cell formation was also favorably reduced resulting from

• The potential use of derivatives belonging to this series as

  2024-08-01

  

  The potential use of derivatives belonging to this series as therapeutic agents mostly depends on their pharmacokinetics and pharmacodynamics. The pharmacokinetic phase includes absorption, distribution, metabolism and excretion (ADME) of the studied compounds. Therefore, preliminary data for theore

• Though we have proved that VA

  2024-08-01

  

  Though, we have proved that VA could suppress hepatic gluconeogenesis, the mechanisms of VA on gluconeogenesis in vivo and in vitro remain unclear. AMP-activated protein kinase (AMPK), which is called an energy receptor enzyme, is widely expressed in liver and other tissues [23]. AMPK has become ano

• To better understand the pathophysiology of ASDs we would ne

  2024-08-01

  

  To better understand the pathophysiology of ASDs, we would need comprehensive information on a) the functions of ASD-associated proteins in the brain, b) how mutations affect the expression level and function of these proteins, c) how mutations affect their function in neurons, and d) how changed ne

• evofosfamide br Autophagy and cell death pathways in ischemi

  2024-07-31

  

  Autophagy and cell death pathways in ischemic stroke Although very important for the effects on post-ischemic evofosfamide injury, autophagy is not the only mechanism of action involved in cell death. Necrosis and apoptosis are two other distinct forms of cell death with great difference in morp

• Along with the improvement of the cadmium transport

  2024-07-31

  

  Along with the improvement of the cadmium transport from roots to aerial tissues, as is required for phytoremediation, over-expression of PtoHMA5 also led to the excessive accumulation of cadmium in leaves that was harmful to plant growth and physiological performance. Thus, detoxification of the he

• There are two major isoforms of LO in mammalian and

  2024-07-31

  

  There are two major isoforms of 12/15-LO in mammalian, 12 and 15- LO, with different cellular distributions. To determine the relative contributions of these isoforms towards glucose-induced monocyte-endothelial interactions, the distribution of these isoforms in the two cell types involved in leuko

• PR-957 In pancreatic islets we found

  2024-07-31

  

  In pancreatic islets we found an increase in protein expression of leukocyte 12/15-LO that paralleled the metabolic decline characterized by severe hyperglycemia and reduced islet numbers. Similar increase in 12/15-LO expression by Western blot was found in the control mice, which have a normal meta

• br Disclaimer Statement br Acknowledgments br Introduction M

  2024-07-31

  

  Disclaimer Statement Acknowledgments Introduction Metabolic changes are a common feature of cancerous tissues. Mutations in oncogenes and tumor suppressor genes cause alterations to multiple intracellular signaling pathways that rewire tumor cell metabolism and re-engineer it to allow enhan

• Tumor suppressor ARF regulates the activity of

  2024-07-31

  

  Tumor suppressor ARF regulates the activity of p53 by inhibiting the functions of Mdm2. ARF is induced by hyperproliferative signals emanating from oncogenic Ras, overexpressed c-myc, and from deregulated E2F . ARF prevents p53 degradation and leads to increased p53 function by sequestering Mdm2 to

• AP activation is known to

  2024-07-31

  

  AP-1 activation is known to upregulate downstream target genes including NS 1738 D1, c-myc, Bcl-xl, MMP-9, EGFR, and specific miRNAs that are involved in progression and metastasis of tumors. Moreover, matrix metalloproteinase-2 has been shown as a downstream gene of AP-1, triggered by 15-HETE in th

13495 records 108/900 page Previous Next First page 上5页 106107108109110 下5页 Last page